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Abstract: Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. 
The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-
B inhibitor, used for the treatment of the early stage of Parkinson’s disease and senile dementia was investigated using 
thin layer chromatography. 
Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at 
least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single 
oral dose of 5 mg/kg 
14C-(methyl)-labeled (-)-deprenyl, 98 μCi/mg. Diabetic rats excreted the majority of urinary radioac-
tivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using 
thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly com-
pared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients 
suffering from diabetes. 
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INTRODUCTION 
  The route and mode of elimination of some drugs such as 
paracetamol has been studied in the saliva of type 1 and type 
2 diabetic patients [1] and diflunisal in animal model of dia-
betes [2]. In most of the reports on drug elimination, the con-
troversial issues are the kinetics, route of elimination, me-
tabolite formation and the mechanism by which they are 
eliminated. 
  Oxidative N-demethylation is one of the basic metabolic 
reactions of both xenobiotics and endogenous compounds of 
vertebrates [3-5]. Removal of the methyl group decreases the 
lipophilicity of the compounds, thereby facilitating their ex-
cretion. A classical model of metabolic demethylation is 
methylamine which is generated endogenously [5]. The 
sources of methylamine include adrenaline, creatinine and 
sarcosine [5]. 
  Metabolic studies on drugs and food components have 
dealt mainly with the identification and quantitative determi-
nation of the N-demethylated compounds [3-6]. Much less, if 
any attention has been focused on the fate of the molecular 
fragment derived from the methyl group. However, it is well 
known that formaldehyde is produced by N-demethylation 
and has been widely cited by many textbooks of pharmacol-
ogy. The generated formaldehyde was easily identified when  
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the N-methyl group was 
14C radiolabelled; and certain N-
demethylation reactions occurred through the homocystein-
methionine cycle resulting in methylation of an endogenous 
compound [5]. 
  Recent publications stated that formaldehyde, formed in 
situ, can directly take part in methylation reactions [5, 7-9]. 
Tyihák E, et al. [7] and Trezli et al. [8] reported a spontane-
ous methylation of N-amino group of lysine by formalde-
hyde. The application of planar chromatography, especially 
two-dimensional thin-layer chromatography has given an 
easy and reliable tool to locate the formaldehyde after pre-
chromatography reaction with dimedone [10-13]. Although, 
formaldehyde was eliminated in urine, further reaction also 
took place in which a basic amino acid (lysine) is the major 
target. The methylation of lysine results in N
-monomethyl-
lysine, which was identified using thin-layer chromatogra-
phy and high-performance liquid chromatography combined 
with mass spectrometry detection (HPLC-MS) [14-17]. Di-
rect verification of the N-methyl transfer from the drug [(-)-
deprenyl] to lysine was also done using 
14C-methyl labeled 
deprenyl, and one part of the radioactivity was detected on 
the N-monomethyllysine. 
  Studies by Yu et al. [18,19] detailed the significance of 
semicarbazide-sensitive amine oxidase (SSAO) in the gen-
eration of formaldehyde from exogenous and endogenous 
compounds as well as the level of SSAO in Type 2 diabetes 
mellitus. Other investigators reported the association of se-
rum monoamine oxidase level and retinopathy in diabetes 
mellitus [20]. 2    The Open Medicinal Chemistry Journal, 2008, Volume 2  Adeghate et al. 
  The present report examined the effect of diabetes melli-
tus on the urinary excretion of radiolabelled deprenyl [(R)-(-
)-
14C-N-methyl-2-methyl-N-propynyl-phenylethylamine 
hydrochloride]. 
MATERIALS AND METHODS 
Solvents and Chemicals 
  All solvents were of HPLC grade of purity, purchased 
from E. Merck (Darmstadt, Germany). HPLC grade water 
was used. 
Methods 
Treatments 
  Male Wistar rats (180-200 g) were treated per os with 5 
mg/kg radiolabelled L-deprenyl. Urine was collected at 2, 4, 
6, 8, 16 and 24 hours after the administration of radiolabelled 
L-deprenyl. 
  Male Wistar rats (180-200 g) were rendered diabetic by 
streptozotocin (STZ) treatment (60 mg/kg, i.v.). Blood glu-
cose level and body weight were monitored weekly. Rats 
having at least three times higher plasma glucose than the 
normal ones were considered diabetic. Control rats did not 
receive STZ. Both diabetic and control rats were adminis-
tered with a single oral dose of 5 mg/kg 
14C-(methyl)-labeled 
(-)-deprenyl, 98 μCi/mg. Drinking water supply to rats was 
ad libitum. Animal treatment was conducted under protocols 
in accordance with the Guide for Care and Use of Laboratory 
Animals (Semmelweis University, Budapest, Hungary). Af-
ter the protocol was supervised by the Ethical Committee of 
Animal Research, the permission was granted by Budapest 
Animal Health and Food Control Station, Budapest, Hungary 
(No. 1810/003/2004), 
  Metabolites were identified and quantified using thin-
layer chromatography (TLC) on TLC silica plates F254, 20 x 
20 cm (E. Merck), developed with chloroform—methanol—
water (7:5:1, 1
st dimension) and (triethanolamine—
chloroform (5:95, 2
nd dimension, displacement development) 
mobile phases. The spots on the TLC plates were evaluated 
using digital autoradiography (DAR of Berthold, Germany). 
Pre-Column Derivatization with Fmoc Chloride 
  To every 2 mL urine sample, 1 mL potassium borate 
buffer (0.8 M, pH 10) was added, and the mixture was vig-
orously shaken for 1 min using a mixer. Fmoc chloride solu-
tion in acetonitrile (2 mL, 10 mM) was then added, and vor-
texed immediately for 1 min. Subsequently 2 mL n-hexane 
was added, the mixture shaken for 1 min, and the upper and 
lower phases were separated by centrifugation. The upper 
(organic) phase containing the excess of Fmoc reagent was 
discarded. The n-hexane extraction was repeated twice. Fi-
nally, 200 μL of acetic acid (10%, v/v) was added to the 
samples, mixed, and 100 μL sample was subjected to HPLC 
separation. The solution of standard N
-Methyllysine HCl 
was also carried out through an identical derivatization proc-
ess. 
HPLC 
  A JASCO system (JASCO Corporation, Tokyo, Japan) 
consisting of a DG-208054 degasser, PU-1580 pump,   
 
AS-2057 plus automatic sample injector, and UV-1575 de-
tector at 265 nm were used. Chromatographic data were 
stored and evaluated using the SRI Model 202 Peak Simple 
Chromatographic Data System (SRI Instruments, Torrance, 
CA, USA). The standard N
-Monomethyl- lysine HCl and 
urine samples were separated after derivatization with Fmoc 
hydrochloride. HPLC was carried out using a 25 cm x 4.6 
mm I.D. column packed with 6 μm Kovasil C18 endcapped 
particles (Chemie Uetikon, Uetikon, Switzerland) to separate 
the radioactive (
14C-labelled monomethyllysine) peak of the 
urine using acetonitrile—water (2:1), which also contain 
0.1% formic acid as the mobile phase. The HPLC column 
was kept at 28 ºC. The mobile phase flow rate was 1.5 mL 
min
-1, and each fraction was collected for 1 min. 
RESULTS 
  Rat urine was collected following oral administration of 
14C-(methyl)-labeled (-)-deprenyl, and the cumulative excre-
tion of radioactivity was determined. Urinary elimination of 
radiolabelled-deprenyl was significantly (p < 0.05) faster in 
the first 8 hours after oral administration of 
14C-(methyl)-
labeled (-)-deprenyl, when compared to controls (Fig. 1). 
STZ-induced diabetes facilitated urinary elimination of the 
radioactivity. The rat urine (containing radiolabelled-dep-
renyl and its metabolites) was subjected to two-dimensional 
thin-layer chromatography after reacting it with dimedon, 
and radioactive spots were located using an X-ray film (Fig. 
2). The spots were scarped, and their ratios were compared. 
Fig. (3) showed the major metabolites of deprenyl. The ratio 
of methamphetamine, p-hydroxy-metham-phetamine, de-
prenyl and formaldehyde were 20:3:1:1 in the urine collected 
for 8 hours (Table 1). Urine eliminated radioactivity in N-
monomethyllysine was determined using HPLC, its amount 
was about 10% of the free urinary formaldehyde. 
 
 
Fig. (1). The time course of urinary excretion of radioactivity when 
the N-methyl group of (-)-deprenyl was 
14C-labelled. 
DISCUSSION 
  There are two major metabolites of (-)-deprenyl. The 
detection of these metabolites depends on the analytical   
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Fig. (2). Thin-layer chromatography of radiolabelled deprenyl me-
tabolites. 
method applied. Reynolds et al. [21] detected metham-
phetamine about 30 years ago, as the major deprenyl me-
tabolite in man. They used GC-MS (gas chromatography 
combined with mass spectrometry), so their method did not 
make it possible to find the other major deprenyl metabolite, 
deprenyl-N-oxide that was later identified by Katagi et al. 
[22]. Unfortunately, deprenyl-N-oxide cannot be detected 
using thin-layer chromatography either. Other deprenyl me-
tabolites include para-hydroxy-methamphetamine, nor-
deprenyl (also called desmethyldeprenyl), amphetamine, and 
phenylacetone. However, the radiolabelled N-methyl group 
is present only in para-hydroxy-methamphetamine. Moreo-
ver, Szatmári described 25 deprenyl metabolites with aro-
matic ring, as well as two more fragments containing the 
propargyl (N-methyl-propargylamine and propargylamine) 
as well as propiolaldehyde [23]. If we also calculate the con-
jugates of several deprenyl metabolites (mainly that of p-
hydroxy-metabolites), the gross number of metabolic prod-
ucts can approach 40. 
  It is peculiar that previous studies on deprenyl metabo-
lism neglected an evident metabolite of deprenyl, the for-
maldehyde. In fact, most of the basic textbooks on pharma-
cology show that formaldehyde is a byproduct of R-X-CH3 
splitting, where the R-X-CH3 R-X-H + CH2O reaction can be 
either N-demethylation, or O-demethylation or S-demethy-
lation [3, 4, 6]. 
  Our earlier papers have shown that 
14C-labelled deprenyl 
is generated from 
14C-labelled (-)-deprenyl which is elimi-
nated in urine. Moreover, one of the radiolabelled peaks of 
the same rat urine was 
14C-labelled-N
-monomethyl- lysine. 
Identification of N
-monomethyllysine in the urine as well as 
in isolated homogenous peak with radioactivity was done by 
the use of two different HPLC-MS techniques that used elec-
trospray (ES) ionization [24] as well as atmospheric pressure 
chemical ionization (APCI) modes [17]. It is also worth not-
ing that the generated compounds were present in the urine 
only in traces (formaldehyde, about 1 to 2% of radioactivity 
administered, and N
-monomethyllysine, about 0.1%). 
  The responsible enzyme of oxidative demethylation (or 
one of the responsible enzymes) is semicarbazide-sensitive 
amine oxidase (SSAO; EC.1.4.3.6), which shows an elevated 
level in the blood of diabetic patients [25, 26]. 
  In contrast, hepatic cytochrome P450 activity of amino-
pyrine N-demethylase and ethoxyresorufin O-deethylase 
enzymes showed changes in opposite directions after the 
onset of STZ-induced diabetes. Aminopyrine N-demethylase 
activity significantly decreased [2.88+0.16 (control), 
2.19+0.46 (after treatment with 50 mg/kg STZ, p0.001) and 
1.53+0.22 (after treatment with 70 mg/kg STZ, p0.001)], 
while ethoxyresorufin O-deethylase activity increased 
[49.6+5.0 (control), 73.3+12.6 (after treatment with 50 
mg/kg STZ, p0.01) and 82.6+14.9 (after treatment with 70 
mg/kg STZ, p0.01)]. 
   
Fig. (3). Major metabolic routes and metabolites of (-)-deprenyl. (The number in bracket corresponds to those in Table 1) 4    The Open Medicinal Chemistry Journal, 2008, Volume 2  Adeghate et al. 
 Watanabe  et al. [27] reported that the change in pharma-
cokinetics after STZ-induced diabetes tmax became shorter, 
however, Cmax and the area under the time versus concentra-
tion curve (AUC) became higher in the case of diabetic rats 
compared to control rats. Watanabe et al. [27] also compared 
the parameters of pharmacokinetics in the spontaneously dia-
betic (GK-rats, NIDDM model) and Zucker rats (almost nor-
mal glycemic but abnormally glucose tolerant, hyperinsuline-
mic, increasingly obese, insulin-resistant rats). These rats 
showed even shorter t, but higher Cmax and AUC parameters. 
CONCLUSION 
  Urinary elimination of (-)-deprenyl and its metabolites 
was faster in STZ-induced diabetic rats compared to control. 
As the metabolites and their ration was not changed, more 
frequent treatment with lower dose, or the use of sustained 
release preparations can counterbalance the faster elimina-
tion of deprenyl and possibly other drugs used in diabetes. 
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